AR099416A1 - COMBINED THERAPY FOR RESISTANT HYPERTENSION - Google Patents

COMBINED THERAPY FOR RESISTANT HYPERTENSION

Info

Publication number
AR099416A1
AR099416A1 ARP150100429A ARP150100429A AR099416A1 AR 099416 A1 AR099416 A1 AR 099416A1 AR P150100429 A ARP150100429 A AR P150100429A AR P150100429 A ARP150100429 A AR P150100429A AR 099416 A1 AR099416 A1 AR 099416A1
Authority
AR
Argentina
Prior art keywords
resistant hypertension
combined therapy
patient
methyl
formula
Prior art date
Application number
ARP150100429A
Other languages
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR099416A1 publication Critical patent/AR099416A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de la hipertensión resistente en un paciente, caracterizado porque comprende administrar a un paciente en necesidad de tal tratamiento una cantidad eficaz del compuesto [5-[(E)-(3-fluoro-6H-benzo[c][2]benzoxepin-il-ilideno)metil]-1-[(1R)-1-metil-2-morfolino-etil]benzimidazol-2-il]urea, representado estructuralmente por la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en combinación con una cantidad eficaz de Tadalafil, representado estructuralmente por la fórmula (2).Claim 1: A method of treating resistant hypertension in a patient, characterized in that it comprises administering to an patient in need of such treatment an effective amount of the compound [5 - [(E) - (3-fluoro-6H-benzo [c ] [2] benzoxepin-yl-ylidene) methyl] -1 - [(1R) -1-methyl-2-morpholino-ethyl] benzimidazol-2-yl] urea, structurally represented by the formula (1) or a pharmaceutically salt acceptable thereof, in combination with an effective amount of Tadalafil, structurally represented by the formula (2).

ARP150100429A 2014-02-28 2015-02-12 COMBINED THERAPY FOR RESISTANT HYPERTENSION AR099416A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946061P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
AR099416A1 true AR099416A1 (en) 2016-07-20

Family

ID=52684674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100429A AR099416A1 (en) 2014-02-28 2015-02-12 COMBINED THERAPY FOR RESISTANT HYPERTENSION

Country Status (2)

Country Link
AR (1) AR099416A1 (en)
WO (1) WO2015130568A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110790764B (en) * 2019-11-27 2021-04-06 四川省通园制药集团有限公司 Method for preparing tadalafil by one-pot method
CN111253399A (en) * 2020-03-30 2020-06-09 苏州弘森药业股份有限公司 Production process of tadalafil raw material medicine
CN113582992A (en) * 2021-06-11 2021-11-02 山东罗欣药业集团股份有限公司 Preparation method of phosphodiesterase inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
DZ3179A1 (en) 1999-08-03 2001-02-08 Lilly Icos Llc Pharmaceutical compositions based on beta-carboline.
MXPA05001139A (en) 2002-07-31 2005-05-16 Lilly Icos Llc Modified pictet-spengler reaction and products prepared therefrom.
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
PE20091057A1 (en) 2007-12-19 2009-07-20 Lilly Co Eli MINERALCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE

Also Published As

Publication number Publication date
WO2015130568A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
CO2019015090A2 (en) Treatment methods for cystic fibrosis
MX2017004471A (en) Triazolopyridine compounds and methods for the treatment of cystic fibrosis.
ES2721001T3 (en) Isoindoline derivative, and compositions and methods to treat a neurodegenerative disease
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
CR20150416A (en) CDC7 INHIBITORS
AR094970A1 (en) AN MDM2 INHIBITOR DERIVED FROM BENZOIC ACID FOR CANCER TREATMENT
AR103680A1 (en) BACE1 SELECTIVE INHIBITORS
SV2018005682A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
EA201691481A1 (en) C5a inhibitors for the treatment of viral pneumonia
CR20140086A (en) COMBINATION TREATMENTS FOR HEPATITIS C
CL2017000050A1 (en) Combination Therapy for Cancer
NI201800071A (en) ISOINDOL COMPOUNDS
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
CL2019002325A1 (en) Pharmaceutical combinations to treat cancer.
AR092103A1 (en) LAQUINIMOD IN THE TREATMENT OF DISORDERS MEDIATED BY THE CANABINOID RECEIVER OF TYPE 1 (CB1)
MX2019002369A (en) Compounds for treating diseases associated with a mitochondrial dysfonction.
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
AR099416A1 (en) COMBINED THERAPY FOR RESISTANT HYPERTENSION
SV2018005701A (en) 1,3,4-TIADIAZOL COMPOUNDS AND THEIR USE IN CANCER TREATMENT
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
ES2721003T3 (en) Use of 1,3-propane disulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
PE20170586A1 (en) NEW USE OF N, N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.

Legal Events

Date Code Title Description
FB Suspension of granting procedure